Paula M. Flaherty
Angiogenesis is the process by which a new blood supply is established from pre-existing blood vessels. It is initiated by degradation of vessel basement membrane, endothelial cell proliferation, invasion, and directional migration towards chemoattractants, tube formation, and finally the establishment of a new vasculature.
We will discuss a portfolio of Corning products designed to investigate specific stages of angiogenesis through standardized and quantitative in vitro cell-based assays.
•HUVEC-2 Endothelial Cells—Widely studied endothelial cells that have been pre-screened for responsiveness to VEGF, a prototypic stimulator of angiogenesis
•ECMs and Chemoattractants—ECMs and key pro-angiogenic chemoattractants for optimal EC propagation, attachment, differentiation, and other key functions
•Endothelial Cell Invasion and Migration Assays—An enabling platform technology consisting of Corning® FluoroBlok™ microporous permeable supports coated with our unique extracellular matrix proteins for quantitation of endothelial cell migration and invasion
•Endothelia Cell Tube Formation Assay—A rapid assay system allowing direct screening of angiogenic compounds for their effects on endothelial cell tube formation
Paula Flaherty is a Technology Manager at Corning Life Sciences. Her team develops strategy and products focused on the modulation of in vitro cell behavior using extracellular matrix, media, vessel design, and growth factors. Prior to joining Corning Life Sciences, Paula studied retinal degeneration at the Berman-Gund Laboratory, Harvard Medical School in Boston, MA. She received her bachelor’s degree in Microbiology from the State University of New York and is an In Vitro Cell Biology Fellow, W. Alton Jones Cell Science Center in Lake Placid, NY.